Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies

McInnes, Matthew D F; Moher, David; Thombs, Brett D; McGrath, Trevor A; Bossuyt, Patrick M; Clifford, Tammy; Cohen, Jérémie F; Deeks, Jonathan; Gatsonis, Constantine; Hooft, Lotty; Hunt, Harriet A; Hyde, Christopher J; Korevaar, Daniël A; Leeflang, Mariska M G; Macaskill, Petra; Reitsma, Johannes B; Rodin, Rachel; Rutjes, Anne W S; Salameh, Jean-Paul; Stevens, Adrienne

DOI: 10.1001/jama.2017.19163

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Checked for eligibility: 20/02/2018
https://jamanetwork.com/journals/jama/fullarticle/2670259

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?).
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 10. Dec. 2018
Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies
The PRISMA-DTA Statement

Matthew D. F. McInnes, MD; David Moher, PhD; Brett D. Thombs, PhD; Trevor A. McGrath, BSc; Patrick M. Bossuyt, PhD; and the PRISMA-DTA Group

IMPORTANCE Systematic reviews of diagnostic test accuracy synthesize data from primary diagnostic studies that have evaluated the accuracy of 1 or more index tests against a reference standard, provide estimates of test performance, allow comparisons of the accuracy of different tests, and facilitate the identification of sources of variability in test accuracy.

OBJECTIVE To develop the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagnostic test accuracy guideline as a stand-alone extension of the PRISMA statement. Modifications to the PRISMA statement reflect the specific requirements for reporting of systematic reviews and meta-analyses of diagnostic test accuracy studies and the abstracts for these reviews.

DESIGN Established standards from the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network were followed for the development of the guideline. The original PRISMA statement was used as a framework on which to modify and add items. A group of 24 multidisciplinary experts used a systematic review of articles on existing reporting guidelines and methods, a 3-round Delphi process, a consensus meeting, pilot testing, and iterative refinement to develop the PRISMA diagnostic test accuracy guideline. The final version of the PRISMA diagnostic test accuracy guideline checklist was approved by the group.

FINDINGS The systematic review (produced 64 items) and the Delphi process (provided feedback on 7 proposed items; 1 item was later split into 2 items) identified 71 potentially relevant items for consideration. The Delphi process reduced these to 60 items that were discussed at the consensus meeting. Following the meeting, pilot testing and iterative feedback were used to generate the 27-item PRISMA diagnostic test accuracy checklist. To reflect specific or optimal contemporary systematic review methods for diagnostic test accuracy, 8 of the 27 original PRISMA items were left unchanged, 17 were modified, 2 were added, and 2 were omitted.

CONCLUSIONS AND RELEVANCE The 27-item PRISMA diagnostic test accuracy checklist provides specific guidance for reporting of systematic reviews. The PRISMA diagnostic test accuracy guideline can facilitate the transparent reporting of reviews, and may assist in the evaluation of validity and applicability, enhance replicability of reviews, and make the results from systematic reviews of diagnostic test accuracy studies more useful.


© 2018 American Medical Association. All rights reserved.

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The PRISMA-DTA Group authors and investigators appear at the end of the article.

Corresponding Author: Matthew D. F. McInnes, MD, Ottawa Hospital-Civic Campus, 1053 Carling Ave, Ottawa, ON K1E 4Y9, Canada (mmcinnes@toh.ca).
ystematic reviews can advance the understanding of diagnostic test accuracy. Systematic reviews of diagnostic test accuracy synthesize data from primary studies to provide insight into the ability of medical tests to detect a target condition; they also can provide estimates of test performance, allow comparisons of the accuracy of different tests, and facilitate the identification of sources of variability. The number of systematic reviews of diagnostic test accuracy studies has increased rapidly; however, they are often not reported completely, which has contributed to “a crisis of repeatability.”

Reporting of systematic reviews should be complete and informative to enable readers to assess the quality of methods and the validity of the findings. Published systematic reviews of diagnostic test accuracy often have been uninformative and of heterogeneous quality. They demonstrate variability in approaches to fundamental methodological steps, including methods to assess risk of bias, assessment of between-study variability, and methods for combining data across studies.

To improve the reporting of systematic reviews, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was published, which contained a 27-item checklist and flow diagram. The initial PRISMA guideline was focused on improving the quality of systematic reviews of intervention studies; the authors of the original PRISMA statement suggested modification for diagnostic test accuracy reviews. Although systematic reviews of diagnostic test accuracy studies share elements with those of intervention studies, there are important differences. Study design and measures of effect differ from those of randomized clinical trials. Accuracy can differ between studies due to differences in patients, setting, prior testing, and use of different reference standards. Consequently, the methods for evaluating risk of bias, summarizing results, and exploring variability for diagnostic test accuracy studies differ from those used for intervention studies. As such, some PRISMA items are not appropriate for systematic reviews of diagnostic test accuracy studies, others need adaptation, and some areas may not be covered.

We aimed to develop the PRISMA diagnostic test accuracy guideline as a stand-alone extension of the PRISMA statement, modified to reflect the particular requirements for the reporting of diagnostic test accuracy studies in systematic reviews. A secondary objective was to identify items that should be included in the abstracts of systematic reviews of diagnostic test accuracy studies.

### Methods

After establishing the PRISMA diagnostic test accuracy executive group, which was composed of the lead author of the PRISMA statement (D.M.), the lead author of the Standards for the Reporting of Diagnostic Accuracy Studies (STARD) (P.M.B.), an experienced author, reviewer, and editor of systematic reviews of diagnostic test accuracy studies (M.D.F.M.), a number of experts were contacted to join the PRISMA diagnostic test accuracy group and assist with the project (all contacted experts agreed to participate). The goal was to assemble a team of experts in diagnostic test accuracy research and systematic review methods, complemented by authors, journal editors, funders, and users of systematic reviews of diagnostic test accuracy studies. The 24 members and their relevant expertise appear in Table 1 in the Supplement.

The PRISMA diagnostic test accuracy executive group registered the protocol. Established standards from the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network were followed in the development of the guideline; no major deviations from the protocol occurred. The PRISMA diagnostic test accuracy group used the original PRISMA statement as a starting point and endeavored to identify items that needed to be added, removed, or modified to improve systematic reviews of diagnostic test accuracy studies.

Details of the systematic review for item generation have been published elsewhere. To identify articles pertaining to the methods or reporting quality of systematic reviews of diagnostic test accuracy studies, searches of multiple databases and existing sources of guidance (eg, PRISMA, STARD 2015) were performed. After performing data extraction from these reports, potential PRISMA diagnostic test accuracy items were categorized according to specific reporting topics: general overview, quality of reporting, search, variability, pooling methods, publication bias, risk of bias, and other. This list of potential PRISMA diagnostic test accuracy items was presented during the first round of the Delphi process.

### Delphi Process

A 3-round Delphi process was held between December 2016 and March 2017 in which all members of the PRISMA diagnostic test accuracy group were invited to participate. This modified Delphi process has been used previously for similar work such as Risk of Bias in Systematic Reviews and STARD 2015. The aim of the process was to achieve consensus on essential items that should be included in the PRISMA diagnostic test accuracy guideline and to identify items that required discussion at the consensus meeting.

During each round of the survey process, potential essential items were proposed, and participants were asked to score each item on a Likert scale anchored at (1) “not essential to report in a systematic review of diagnostic test accuracy studies” and (5) “essential to report in a systematic review of diagnostic test accuracy studies.”
accuracy studies.” Likert scores of 1 to 2 were categorized as a low score (item should not be part of PRISMA diagnostic test accuracy guideline); 3, moderate (item should be discussed), 4 to 5, high score (item should be part of PRISMA diagnostic test accuracy guideline). For an item to meet consensus, more than 66% of the Delphi respondents (>15 of 23) needed to rate 1 of these 3 categories; this threshold was based on what was used for previous reporting guidelines.24

During round 1 of the Delphi process, all items identified during the systematic review step were proposed.99 Participants were also asked to suggest any additional items that were potentially relevant to report in systematic reviews of diagnostic test accuracy studies. Round 2 of the survey included any items that did not reach consensus during round 1, and any new items suggested by at least 1 respondent during round 1. As with round 2, round 3 involved items that did not reach consensus during rounds 1 or 2.

Following each of the 3 rounds, the mode (most frequent) score for each item was tabulated. Items were categorized as follows: (1) mode score of 1 to 3 but for less than 66% of participants, proceed to next round of Delphi process (or to a meeting discussion if this occurred during round 3 of the Delphi process); (2) consensus score of 1 or 2, do not include; (3) consensus score of 3, discuss at meeting; (4) mode score of 4 or 5 but for less than 66% of participants, discuss at meeting; and (5) consensus score of 4 or 5, include in PRISMA diagnostic test accuracy guideline (but discuss at meeting to confirm exact wording). All participants were provided an anonymized summary of the results after each round of the process. The survey was administered by SurveyMonkey Inc.

Consensus Meeting
A 2-day consensus meeting was held in Amsterdam, the Netherlands, in May 2017 and all members of the executive and PRISMA diagnostic test accuracy group were invited to attend. The main objective of this meeting was to agree on items for which no consensus was reached during the Delphi survey process and to generate a preliminary PRISMA diagnostic test accuracy checklist guideline (and a guideline for abstracts). For the items that reached consensus for inclusion prior to the meeting, the precise wording of the items was decided.

Checklist Pilot
Following the meeting, members of the PRISMA diagnostic test accuracy group reviewed and applied the checklist to ongoing systematic reviews of diagnostic test accuracy studies to identify any practical challenges with any of the items and to inform the writing of the statement. This included formal pilot testing by a graduate student (J-P.S.) of the preliminary checklist used to assess published systematic reviews of diagnostic test accuracy studies.

In addition, multiple potential users and interested parties (such as authors of systematic reviews and attendees of an author training course on conducting systematic reviews of diagnostic test accuracy studies) were invited to review and apply the preliminary checklist to assess utility and clarity of wording. Feedback from these pilot exercises was used to refine wording and presentation of the checklist. Formal feedback was gathered via email correspondence. All sources of feedback were used to modify and inform the final version of the PRISMA diagnostic test accuracy checklist.

A further explanation and elaboration document will subsequently be developed to provide additional detail regarding the rationale for the items and examples. Based on government and institutional guidelines, this type of study does not require research ethics board approval.

Results
Delphi Process
Twenty-three of 23 individuals (100%) completed all 3 rounds of the Delphi process (participation is documented in eTable 1 in the Supplement). During round 1, the group evaluated 64 items identified by the systematic review (Figure). Forty-two items met consensus for inclusion, 20 items were moved forward to round 2, 2 items were excluded, and an additional 6 items were suggested for inclusion for round 2.

During round 2, the group assessed 27 items (1 item from round 1 was split into 2 items for round 2). There were 5 items that met consensus for inclusion, 15 items were moved forward to round 3, and 7 items were excluded. During round 3, no items met consensus for inclusion. 15 items were moved forward to round 3.
inclusion, 13 items were moved forward to the consensus meeting, and 2 items were excluded. Overall, after 3 Delphi rounds, 47 items were included (final wording to be discussed at the face-to-face consensus meeting), 13 items were moved forward to the consensus meeting to discuss inclusion or exclusion, and 11 items were excluded.

A list of the 11 excluded items appears in eTable 2 in the Supplement. Even though these items are considered relevant to the reporting of systematic reviews of diagnostic test accuracy studies, they were considered to be either too detailed for a minimum reporting guideline or not relevant depending on the scope or purpose of the review. Several of these items will be discussed further in the forthcoming explanation and elaboration document.

Consensus Meeting

Meeting attendance (n = 18) and the agenda are documented in eTables 1 and 3 in the Supplement, respectively. Of the 60 items discussed at the meeting, 27 were excluded. Excluded items and the rationale for exclusion are provided in eTable 2 in the Supplement.

Items 15 and 22 from the original 27-item PRISMA checklist were confirmed for removal. These items refer to the evaluation and reporting of risk of bias that may affect the cumulative evidence such as publication bias and selective reporting within studies. They were excluded for 2 main reasons. First, there is only limited evidence that publication or reporting bias is a major issue for primary diagnostic test accuracy studies.25,26 As such, the rationale for mandating evaluation of bias in systematic reviews of diagnostic test accuracy studies is not as strong as for reviews of intervention studies. Second, there is no appropriate test with adequate statistical power to reliably assess publication bias in the context of diagnostic test accuracy systematic reviews.27,29

The remaining 33 items were discussed and synthesized into a draft checklist for PRISMA diagnostic test accuracy. Many of the items were combined to reduce redundancy between items and to minimize the total number of items. The PRISMA flow diagram was also reviewed at the consensus meeting and no modifications for PRISMA diagnostic test accuracy were deemed necessary.

Compared with the original PRISMA checklist, 2 new items were added. The first, labeled item D1, regards the statement of the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative reviews). The rationale for inclusion is 2-fold. First, the role of the index test is critical to understanding the place of a test in the diagnostic pathway; diagnostic accuracy can vary importantly depending on the clinical scenario. Without this information, generalizability of the results to the clinical setting may be limited.16,30 Second, identifying minimally acceptable test accuracy may be helpful in forming conclusions. Whether a test is considered clinically useful cannot be determined by a diagnostic accuracy measure alone; its accuracy relative to alternative tests or management strategies must be considered, as well as the downstream consequences of false-positive and false-negative results. As such, considering external evidence to form criteria for minimally acceptable test accuracy standards may play an important role in forming the purpose of diagnostic test accuracy systematic reviews.16,30,31

Defining minimally acceptable test accuracy (or minimum difference) may not always be appropriate depending on the review question. For example, if a test is not yet well established or understood, the purpose of the review might be to evaluate reasons for variability in accuracy. For this reason, we have added the qualifier if applicable to this item.

The second new item is labeled item D2 and regards the reporting of the statistical methods used for the meta-analyses if performed. Meta-analyses of diagnostic test accuracy studies typically require multivariate models (eg, bivariate and hierarchical summary receiver operating characteristic), which allow for the tradeoff between sensitivity and specificity due to the positivity threshold, for potential correlation between estimates of sensitivity and specificity across studies, and for variability through the inclusion of random effects.32,33 Traditional univariate methods ignore this correlation and can give misleading results.5,34,35 We acknowledge that there are instances when univariate methods may be appropriate (eg, if the specificity of a test is set at 100%, or if the focus of the review is univariate meta-analysis of sensitivity). As such, reporting the method used for meta-analysis (if done) was considered essential for systematic reviews of diagnostic test accuracy studies.

Eight of the original PRISMA items (3, 5, 7, 9, 10, 16, 17, and 27) were not modified because they were considered to be equally applicable to systematic reviews of diagnostic test accuracy studies. Seventeen of the original PRISMA items (1, 2, 4, 6, 8, 11-14, 18-21, and 23-26) were adapted. The reasons for modification varied. The 2 major reasons were (1) there was unclear or ambiguous wording in the original PRISMA statement that required updating and (2) modified wording was necessary due to specific issues for systematic reviews of diagnostic test accuracy studies. Table 1 lists the rationale for modification of the original PRISMA items for systematic reviews of diagnostic test accuracy. Further explanation and elaboration on the rationale and evidence will be provided in the forthcoming explanation and elaboration document.

At the consensus meeting, the original PRISMA checklist for abstracts was modified for systematic reviews of diagnostic test accuracy studies.38 The total number of items was preserved (n = 12). Five items were not modified (4, 6, 10-12). One item was deleted (8, which was a description of the effect) because effect size is only relevant to intervention studies.1,27 One new item was added (labeled A1, which regards synthesis of results) and corresponds to new item D2 in the PRISMA diagnostic test accuracy checklist. Six items were modified (1-3, 5, 7, and 9) to reflect the modified language for the corresponding items in the PRISMA diagnostic test accuracy checklist.

Pilot Testing and Revision

Thirty-seven points of feedback from the pilot exercise were received via email and formal survey. This feedback was considered by the PRISMA diagnostic test accuracy executive group and used to modify 5 of the items and add further explanation and rationale.

Final Checklists

The final version of the PRISMA diagnostic test accuracy checklist appears in Table 2. The new checklist has the same number of items as the original PRISMA checklist because 2 items were deleted (items 15 and 22) and 2 items were added (items D1 and D2); therefore, the numbering from the original PRISMA statement is preserved.
Table 1. Rationale for Modification of the Original Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement for Diagnostic Test Accuracy (DTA) Studies*

<table>
<thead>
<tr>
<th>Section and Topic</th>
<th>Item No.</th>
<th>Reason for Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>1</td>
<td>Specification that the systematic review pertains to diagnostic test accuracy in the title is considered to enhance clarity of purpose and allow for easy identification when searching for reviews.</td>
</tr>
<tr>
<td>Abstract</td>
<td>2</td>
<td>As per our study objectives, we aimed to create a specific, essential list of items for systematic reviews of DTA studies to be reported in the abstract. As such, we replaced this item with the PRISMA-DTA checklist for abstracts.</td>
</tr>
<tr>
<td>Structured summary</td>
<td>4</td>
<td>The original PRISMA wording (participant, intervention, comparison, outcome; PICO) was intended for systematic reviews of intervention studies. As such, the wording was modified to be more relevant for systematic reviews of DTA studies (eg, index test rather than intervention).</td>
</tr>
<tr>
<td>Introduction</td>
<td>6</td>
<td>Language specific to DTA (modifying PICO as described for item 4) was added.</td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>The primary reason for modification is not specific to DTA, but is for all contemporary systematic reviews. When the original PRISMA statement was written, it was not feasible to publish all electronic strategies. Present-day options for online supplemental material and institutional repositories provide options to report all search strategies, which will enhance transparency, improve replicability, and enable easier updating of systematic reviews.</td>
</tr>
<tr>
<td>Data items</td>
<td>11</td>
<td>Data items and relevant definitions with language specific to and essential regarding study objectives and risk of bias in systematic reviews of DTA studies (index test, target condition) were modified.</td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>12</td>
<td>Individual DTA studies may be at risk of bias and there can also be concerns regarding applicability (as highlighted in QUADAS-2). As such, language to reflect this was added.</td>
</tr>
<tr>
<td>Summary measures</td>
<td>13</td>
<td>Summary measures: 1. The measures provided in PRISMA (eg, risk ratios) are specific to systematic reviews of intervention effectiveness. As such, the wording was modified to reflect measures relevant to assessing diagnostic accuracy (eg, sensitivity). 2. The unit of assessment (per lesion with multiple liver lesion samples treated as individual observations in a 2 × 2 table vs per patient) can be critical in regard to accuracy estimates and generalizability of results due to potential bias introduced from clustering effects in per-lesion analysis. As such, this additional requirement relevant to systematic reviews of DTA studies was added.</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>14</td>
<td>Synthesis of results 1. Measures of consistency (eg, I²) considered routine in reviews of intervention studies are not typically applicable in systematic reviews of DTA studies. There is no consensus regarding alternative statistics. As such, the more general term variability, which can reflect multiple strategies to explore variability, was used in place of the term inconsistency. 2. Additional specific items particular to systematic reviews of DTA studies were considered to be of sufficient relevance to list as requirements. These include describing definitions of the target condition, test positivity, and others.</td>
</tr>
<tr>
<td>Study characteristics</td>
<td>18</td>
<td>Study characteristics considered to be essential regarding risk of bias and applicability in systematic reviews of DTA studies were listed (eg, reference standard, clinical setting). The category of funding sources was added to optimize transparency because industry vs nonindustry funding may be relevant to consider in systematic reviews of DTA studies.</td>
</tr>
<tr>
<td>Risk of bias within studies</td>
<td>19</td>
<td>Individual DTA studies may be at risk of bias and there can also be concerns regarding applicability (as highlighted in QUADAS-2). As such, language to reflect this was added.</td>
</tr>
<tr>
<td>Results</td>
<td>20</td>
<td>Original wording for summary data for each intervention group was specific to systematic reviews of intervention effectiveness. As such, the wording was revised to reflect results relevant to systematic reviews of DTA studies (eg, 2 × 2 data and positivity threshold used). Reporting of 2 × 2 data is required to allow readers to evaluate important variables such as the proportion with the target condition and other accuracy estimates that may not have been specifically addressed in the review (eg, positive predictive value).</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>21</td>
<td>Language was modified to be more specific and relevant to systematic reviews of DTA studies (eg, describe test accuracy). In addition, the term inconsistency was replaced with the preferred term variability (as described in item 14) for systematic reviews of DTA studies.</td>
</tr>
<tr>
<td>Additional analyses</td>
<td>23</td>
<td>In addition to the original PRISMA wording, we ask that additional information (including potential harms) relevant to systematic reviews of DTA studies be reported (eg, index test failures such as inconclusive, unusable, or indeterminate results and adverse events related to index test administration).</td>
</tr>
<tr>
<td>Summary of evidence</td>
<td>24</td>
<td>Wording was simplified to only refer to main findings because there is typically only 1 primary outcome (diagnostic accuracy) in systematic reviews of DTA studies. In addition, relevance to key groups was considered to be more appropriate with item 26; as such, it was modified and moved to item 26.</td>
</tr>
<tr>
<td>Discussion</td>
<td>25</td>
<td>As per discussion for item 12, wording was modified to reflect concerns regarding the term applicability in addition to the term risk of bias.</td>
</tr>
<tr>
<td>Conclusions</td>
<td>26</td>
<td>As per discussion for item 24, implications for clinical practice were considered to be more appropriate in the conclusions. In addition, language specific to the generalizability of the findings for systematic reviews of DTA studies (eg, intended use and clinical role of the index test) was added.</td>
</tr>
</tbody>
</table>

* The final wording for the PRISMA-DTA checklist appears in Table 2 and the abstract checklist appears in Table 3.

© 2018 American Medical Association. All rights reserved.
Table 2. Checklist for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for Diagnostic Test Accuracy (DTA) Studies

<table>
<thead>
<tr>
<th>Section and Topic</th>
<th>Item No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review (meta-analysis) of DTA studies.</td>
</tr>
<tr>
<td>Title</td>
<td>2</td>
<td>A checklist for abstracts appears in Table 3.</td>
</tr>
<tr>
<td>Introduction</td>
<td>3</td>
<td>Describe the rationale for the review in the context of what is already known.</td>
</tr>
<tr>
<td>Clinical role of index test</td>
<td>D1</td>
<td>State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for a comparable design).</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of question being addressed in terms of participants, index test, and target conditions.</td>
</tr>
<tr>
<td>Methods</td>
<td>5</td>
<td>Indicate where the review protocol can be accessed (eg, web address) and provide trial registration number if available.</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>6</td>
<td>Specify study characteristics (participants, setting, index test, reference standards, target conditions, and study design) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility and providing rationale.</td>
</tr>
<tr>
<td>Information sources</td>
<td>7</td>
<td>Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies in the search and the date last searched).</td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>Present full search strategies for all electronic databases and other sources searched, including any limits used so that they can be repeated.</td>
</tr>
<tr>
<td>Study selection</td>
<td>9</td>
<td>State the process for selecting studies (ie, screening, eligibility, whether included in systematic review, and, if applicable, included in the meta-analysis).</td>
</tr>
<tr>
<td>Data collection process</td>
<td>10</td>
<td>Describe the methods of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from the investigators.</td>
</tr>
<tr>
<td>Definitions for data extraction</td>
<td>11</td>
<td>Provide definitions used in data extraction and classifications of target conditions, index tests, reference standards, and other characteristics (eg, study design, clinical setting).</td>
</tr>
<tr>
<td>Risk of bias and applicability</td>
<td>12</td>
<td>Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review question.</td>
</tr>
<tr>
<td>Diagnostic accuracy measures</td>
<td>13</td>
<td>State the principal diagnostic accuracy measures reported (eg, sensitivity, specificity) and state the unit of assessment (eg, per patient vs per lesion).</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>14</td>
<td>Describe the methods of handling the data, combining the results of the studies and describing the variability between studies. This could include, but is not limited to (1) handling of multiple definitions of the target condition, (2) handling of multiple thresholds of test positivity, (3) handling multiple index test readers, (4) handling of indeterminate test results, (5) grouping and comparing tests, and (6) handling of different reference standards.</td>
</tr>
<tr>
<td>Meta-analysis</td>
<td>15</td>
<td>Report the statistical methods used for meta-analyses if performed.</td>
</tr>
<tr>
<td>Additional analyses</td>
<td>16</td>
<td>Describe the methods of the additional analyses (eg, sensitivity or subgroup analyses, meta-regression) if done, indicating which were prespecified.</td>
</tr>
<tr>
<td>Results</td>
<td>17</td>
<td>Provide the numbers of studies screened, assessed for eligibility, included in the review, and included in the meta-analysis if applicable, with reasons for exclusions at each stage, ideally with a flow diagram.</td>
</tr>
<tr>
<td>Study characteristics</td>
<td>18</td>
<td>For each included study, provide citations and present key characteristics including (1) participant characteristics (presentation, prior testing), (2) clinical setting, (3) study design, (4) target condition definition, (5) index test, (6) reference standard, (7) sample size, and (8) funding sources.</td>
</tr>
<tr>
<td>Risk of bias and applicability</td>
<td>19</td>
<td>Present evaluation of risk of bias and concerns regarding applicability for each study.</td>
</tr>
<tr>
<td>Results of individual studies</td>
<td>20</td>
<td>For each analysis in each study (eg, unique combination of index test, reference standard, and positivity threshold), report 2 × 2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest plot or a receiver operating characteristic curve.</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>21</td>
<td>Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals.</td>
</tr>
<tr>
<td>Additional analyses</td>
<td>22</td>
<td>Give results of additional analyses if done (eg, sensitivity or subgroup analyses, meta-regression, analysis of index test, failure rates, proportion of inconclusive results, and adverse events).</td>
</tr>
<tr>
<td>Discussion</td>
<td>23</td>
<td>Summarize the main findings including the strength of the evidence.</td>
</tr>
<tr>
<td>Limitations</td>
<td>24</td>
<td>Discuss limitations from included studies (eg, risk of bias and concerns regarding applicability) and from the review process (eg, incomplete retrieval of identified research).</td>
</tr>
<tr>
<td>Conclusions</td>
<td>25</td>
<td>Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and clinical practice (eg, the intended use and clinical role of the index test).</td>
</tr>
<tr>
<td>Other</td>
<td>26</td>
<td>For the systematic review, describe the sources of funding and other support and the role of the funders.</td>
</tr>
</tbody>
</table>

Abbreviations: FN, false negative; FP, false positive; TN, true negative; TP, true positive.

*Original PRISMA items 15 and 22 were omitted for reasons listed in the Consensus Meeting subsection in the Results section of the text.

a Modified original PRISMA item.

b Unmodified PRISMA item.
c New PRISMA-DTA item.
The PRISMA diagnostic test accuracy checklist provides guidance specific to systematic reviews of diagnostic test accuracy studies. Both the PRISMA diagnostic test accuracy checklist and the checklist for abstracts were developed with multidisciplinary consensus approaches as per best practices for guideline development. The PRISMA diagnostic test accuracy checklist items reflect the concepts, methods, and language specific to systematic reviews of diagnostic test accuracy studies and, if implemented, can help ensure that information for assessment of risk of bias and applicability and can enhance transparency and replicability of systematic reviews of diagnostic test accuracy studies. This work should be of practical use to those who author, review, publish, fund, and implement the results of systematic reviews of diagnostic test accuracy studies. It may also be useful as a guidance for protocols of systematic reviews on diagnostic test accuracy. This checklist is relevant to include for the evaluation of single tests, multiple tests (comparative), and multivariable diagnostic models.

The PRISMA diagnostic test accuracy checklist aims to improve the completeness and transparency of reporting of systematic reviews of diagnostic test accuracy studies. Complete reporting might be associated with review quality; however, they are not inseparable. The understanding and the application of the optimal principles and methods for systematic reviews of diagnostic test accuracy studies are complex and require knowledge acquired from resources beyond a 27-item reporting checklist. Even though guidance is available for conducting systematic reviews of diagnostic test accuracy studies, considerable areas of uncertainty remain (eg, optimal methods for assessing variability, appropriate interpretation of review findings); these areas are likely to evolve based on ongoing and future research. As such, prospective reviewers are encouraged to seek specialized training (eg, Cochrane group author training resources for screening and diagnostic test methods) and to collaborate with those experienced in systematic review methods for diagnostic test accuracy studies.

Conforming to reporting guidelines can be challenging based on journal-level constraints such as limits on words, tables, and figures; however, there is little evidence to indicate that reporting guidelines increase the word count of articles. Methods to ensure complete reporting may include the use of supplementary online material, institutional repositories, and appendices. The PRISMA diagnostic test accuracy guideline represents minimum reporting requirements, rather than a constraint or cap on what should be reported. Additional information that authors consider relevant to their specific review question may also be reported (eg, interobserver agreement for imaging reviews).

Complete reporting of diagnostic test accuracy systematic reviews may be hindered by incomplete reporting in diagnostic test accuracy primary studies. This challenge makes complete
reporting of systematic reviews of diagnostic test accuracy studies more important because readers need to know whether the necessary information from the primary studies was available and whether conclusions can be drawn based on that information.

Limitations

Development of the PRISMA diagnostic test accuracy statement was guided by evidence-based principles when possible; however, when evidence was lacking, we relied on expert opinion. The PRISMA diagnostic test accuracy checklist was designed for all types of diagnostic test accuracy research; some specialties (eg, imaging) may have important items unique to their specialty (eg, interobserver agreement) that were not included in the guideline but should be reported. In addition, as the body of evidence in diagnostic test accuracy research grows, the PRISMA diagnostic test accuracy guideline will need to be updated to reflect these advances.

Conclusions

The 27-item PRISMA diagnostic test accuracy checklist provides specific guidance for reporting of systematic reviews. The PRISMA diagnostic test accuracy guideline can facilitate the transparent reporting of reviews, and may assist in the evaluation of validity and applicability, enhance replicability of reviews, and make the results from systematic reviews of diagnostic test accuracy studies more useful.

ARTICLE INFORMATION
Accepted for Publication: December 6, 2017.

The PRISMA-DTA Group Authors: Tammy Clifford, PhD; Jérémie F. Cohen, MD, PhD; Jonathan J. Deeks, PhD; Constantine Gatsonis, PhD; Lotty Hoof, PhD; Harriet A. Hunt, MSc; Christopher J. Hyde, PhD; Daniel A. Koveara, MD, PhD; Mariska G. M. Leeflang, PhD; Petra Macaskill, PhD; Johannes B. Reitsma, MD, PhD; Rachel Rodin, MD, MPH; Anne W. S. Rutjes, PhD; Jean-Paul Salameh, BSc; Adrienne Stevens, MSc; Yemisi Takwoingi, PhD; Marcello Tonelli, MD, SM; Laura Weeks, PhD; Penny Whiting, PhD; Brian H. Willis, MD, PhD.

Affiliations of The PRISMA-DTA Group Authors: Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (Salameh); Department of Clinical Epidemiology, Biostatistics and Bioinformatics, University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands (Koveara, Leeflang); Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario (Clifford, Weeks); Department of Pediatrics, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris, France (Cohen); Inserm UMR 1153, Research Center for Epidemiology and Biostatistics Sorbonne Paris Cité, Paris Descartes University, Paris, France (Cohen); University of Birmingham, Birmingham, England (Deeks, Takwoingi, Willis); Brown University, Providence, Rhode Island (Gatsonis); Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands (Hoof, Reitsma); University of Exeter, Exeter, England (Hunt, Hyde); University of Sydney, Sydney, Australia (Macaskill); Public Health Agency of Canada, Ottawa, Ontario, Canada (Rodin); Institute of Social and Preventive Medicine, Berner Institut für Hausarztmedizin, Bern, Bern, Switzerland (Rutjes); School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada (Stevens); Translational Research in Biomedicine Program, School of Medicine, University of Split, Split, Croatia (Stevens); University of Calgary, Calgary, Alberta, Canada (Tonelli); University of Bristol, National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West, Bristol, England (Whiting).

Author Affiliations: Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada (McInnes); Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (McInnes, Moher); Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada (Thombs); Department of Psychiatry, McGill University, Montreal, Quebec, Canada (Thombs); University of Ottawa Department of Radiology, Ottawa, Ontario, Canada (McGrath); Department of Clinical Epidemiology, Biostatistics and Bioinformatics, University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands (Bossuyt).

Author Contributions: Dr McInnes had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: McInnes, Moher, McGrath, Bossuyt, Clifford, Cohen, Koveara, Reitsma, Salameh, Takwoingi, Willis.

Acquisition, analysis, or interpretation of data: McInnes, Thombs, McGrath, Cohen, Gatsonis, Hunt, Hyde, Koveara, Leeflang, Reitsma, Rutjes, Salameh, Stevens, Takwoingi, Tonelli, Weeks, Whiting, Willis.

Drafting of the manuscript: McInnes, Moher, McGrath, Bossuyt, Clifford, Cohen, Gatsonis, Salameh, Takwoingi, Willis.

Critical revision of the manuscript for important intellectual content: McInnes, Thombs, McGrath, Bossuyt, Clifford, Cohen, Deeks, Gatsonis, Hoof, Hunt, Hyde, Koveara, Leeflang, Macaskill, Reitsma, Rodin, Rutjes, Salameh, Stevens, Takwoingi, Tonelli, Weeks, Whiting, Willis.

Obtained funding: McInnes, Clifford.

Administrative, technical, or material support: McInnes, Moher, Clifford, Hunt, Salameh, Willis.

Supervision: McInnes, Bossuyt, Takwoingi.

Role of the Funder/Sponsor: None of the funding sources had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.

REFERENCES


